Ad Header



The Pulse of the Pharmaceutical Industry

Catalyst’s neuromuscular drug succeeds in study

Written by: | | Dated: Wednesday, March 15th, 2017


Catalyst Pharma’s neuromuscular drug succeeds in study



Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

The drug, Firdapse, was being tested on seven patients with Musk-MG, a rare subpopulation of MG patients. There are currently no FDA approved therapies for this form of MG.

Catalyst’s shares jumped about 20 percent to $1.40 before the bell on Wednesday.


(Reporting by Divya Grover in Bengaluru; Editing by Savio D’Souza)


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review


Ad Right Bottom

Main Navigation